Tirzepatide, a dual glucagon-like peptide-1 receptor and gastric inhibitory peptide receptor agonist, is an effective treatment for type 2 diabetes mellitus and obesity, resulting in significant improvements in glycated hemoglobin levels and weight reduction. However, gastrointestinal side effects, including delayed gastric emptying, have been reported. Recently, a case of inadequate visualization during esophagogastroduodenoscopy due to substantial food residues in patients treated with tirzepatide has been reported. This study aims to report a patient who underwent a successful esophagogastroduodenoscopy following a 2-month discontinuation of tirzepatide. Previously, the same patient experienced incomplete esophagogastroduodenoscopies due to excessive food residues despite standard preparation. The findings of this study emphasize the challenges associated with the use of tirzepatide for upper gastrointestinal procedures and suggest that the discontinuation of the drug might be necessary to ensure optimal endoscopic evaluation.